Lipton RB, et al. - Here researchers aimed at analyzing data from the COMPASS study, a randomized, double blind, double-dummy, comparative efficacy study that contrasted two active treatments, AVP-825 (breath-powered intranasal delivery of powdered sumatriptan 22 mg) and oral sumatriptan tablets (100 mg). All three longitudinal models used in the study demonstrated that compared to oral sumatriptan, AVP-825 had more favorable nausea outcomes. AVP-825 treatment resulted in more rapid early reductions in overall nausea rates during the first hour, reduced odds of nausea from 30 minutes to 2 hours following treatment and reduced risk of treatment emergent nausea [TEN] compared to oral sumatriptan. These results underscored the significance of separately assessing TEN and Nausea Relief in acute treatment trials of migraine.